UniProtKB/Swiss-Prot O95905: Variant p.Asn501Ser

Protein ecdysoneless homolog
Gene: ECD
Feedback?

Variant information Variant position:

501 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Asparagine (N) to Serine (S) at position 501 (N501S, p.Asn501Ser). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from medium size and polar (N) to small size and polar (S) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Other resources:

Links to websites of interest for the variant.

Variant rs36152134 [ dbSNP | Ensembl ]

Sequence information Variant position:

501 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

644 The length of the canonical sequence.
Location on the sequence:

ITFDADSFLNYFDKILGPRP N ESDSDDLDDEDFECLDSDDD The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         ITFDAD-----------SFLNYFDKILGPRP--NESDSDDLD-DEDFECLDSDDD

Mouse                         ITFDAD-----------SFLNYFDKILGAKP--QESDSEDD

Drosophila                    PQANGSTGLTAKVKKNPSMRKACQRNSVIQP--EEPDSTHV

Slime mold                    YGNGGDDNISFDSNKFMDILKGFTDNNKYDDDYDDDDDDDD

Fission yeast                 YGVKNS-----------------DTDTDSDSLADSDDEIFL

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 644	Protein ecdysoneless homolog
Region	439 – 644	Transcription activation
Region	496 – 537	Disordered
Modified residue	503 – 503	Phosphoserine
Modified residue	505 – 505	Phosphoserine
Modified residue	518 – 518	Phosphoserine
Mutagenesis	481 – 481	I -> A. Decreases transactivation activity.
Mutagenesis	484 – 484	D -> F. Decreases transactivation activity.
Mutagenesis	489 – 489	L -> A. Decreases transactivation activity.
Mutagenesis	503 – 503	S -> A. Greatly impairs in vitro phosphorylation by CK2 and impairs cell cycle regulation activity; when associated with A-505, A-518, A-572, A-579 and A-584.
Mutagenesis	505 – 505	S -> A. Greatly impairs in vitro phosphorylation by CK2 and impairs cell cycle regulation activity; when associated with A-503, A-518, A-572, A-579 and A-584.
Mutagenesis	510 – 510	D -> R. Increases transactivation activity.
Mutagenesis	512 – 512	D -> R. Increases transactivation activity.
Mutagenesis	518 – 518	S -> A. Greatly impairs in vitro phosphorylation by CK2 and impairs cell cycle regulation activity; when associated with A-503, A-505, A-572, A-579 and A-584.
Mutagenesis	520 – 520	D -> P. Increases transactivation activity.

Literature citations
No reference for the current variant in UniProtKB/Swiss-Prot.

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.